- Home
- NVS
NVS
Novartis AG
as 05-08-2025 4:00pm EST
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 230.5B | IPO Year: | 1991 |
| Target Price: | $123.67 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 6.38 | EPS Growth: | -13.29 |
| 52 Week Low/High: | $96.06 - $120.92 | Next Earning Date: | 04-29-2025 |
| Revenue: | $53,222,000,000 | Revenue Growth: | 11.50% |
| Revenue Growth (this year): | 5.88% | Revenue Growth (next year): | 2.07% |
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
10 hours ago
Q1 2025 Schrodinger Inc Earnings Call
GuruFocus.com
14 hours ago
Schrodinger Inc (SDGR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...
Zacks
3 days ago
Novartis (NVS) is a Great Momentum Stock: Should You Buy?
Zacks
3 days ago
Why Novartis (NVS) is a Great Dividend Stock Right Now
MT Newswires
3 days ago
BioNTech Names Ramon Zapata-Gomez as Chief Financial Officer
LA Times
6 days ago
Novartis to buy Regulus Therapeutics for as much as $1.7 billion
TipRanks
7 days ago
Biotech Alert: Searches spiking for these stocks today
Pharmaceutical Technology
7 days ago
Novartis to strengthen renal disease portfolio with Regulus
Compare NVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.